BUREAUCRATS DENYING AUSTRALIANS ACCESS TO HYDROXYCHLOROQUINE + ZINC AS A MEDICAL TREATMENT ARE IN VIOLATION OF THE HELSINKI DECLARATION

Source: Craig Kelly, Facebook

Today in Parliament (90 seconds speech) I spoke on how Australian Health Bureaucrats are in violation of the HELSINKI DECLARATION.

See: WMA declaration of Helsinki ethical principles for medical research involving human subjects

Mr CRAIG KELLY (Hughes) (13:40): I rise to update the House on the latest medical research into hydroxychloroquine. Firstly, a peer-reviewed paper published in the International Journal of Antimicrobial Agents concluded:

‘‘Hydroxychloroquine at low dose in combination with zinc and azithromycin proved to be an effective therapeutic approach against COVID-19’’

This study found that the odds of hospitalisations of the treated patient group was 84 per cent less then the untreated group. Secondly, a study by the Peruvian Ministry of Health found a 43 per cent reduction in death for those who received treatment with hydroxychloroquine and azithromycin.

Despite these latest studies adding to the overwhelming evidence, health bureaucrats continue to deny Australians the right to this medical treatment, claiming it is ‘unproven’.However, even if these bureaucrats are right, their ban is in direct violation of the ethical principles set out in the Declaration of Helsinki, of which section 37 states:‘’

…. where proven interventions do not exist …

the physician, after seeking expert advice, with informed consent from the patient or a legally authorised representative, may use an unproven intervention if in the physician’s judgement it offers hope of saving life, re-establishing health or alleviating suffering.’’

This unprecedented violation of the sanctity of the doctor-patient relationship, denying Australians access to this drug, must end.





Related:

C19study.com update: Now 118 international studies (71 peer reviewed) show positive hydroxychloroquine treatment outcomes

Belgium Study: Low-dose Hydroxychloroquine Therapy and Mortality (Lowered) in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants

Italy Study 3,451 patients: Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

Italian Study: Hydroxychloroquine Cut Death Risk 66 Percent

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories